SQ109: Phase Ib started

NIH's National Institute of Allergy and Infectious Diseases (NIAID) began a double-blind, dose-escalation, U.S. Phase Ib trial to compare 75 or 150 mg of oral SQ109 given once daily for 14 days, 150 m...